吉西他滨加替吉奥联合沙利度胺治疗老年晚期胰腺癌的临床观察

Effect of treatment with Tegafur and gemcitabine plus thalidomide on old patients with advanced pancreatic tumor

目的探讨吉西他滨加替吉奥联合沙利度胺在老年晚期胰腺癌治疗中的临床疗效并观察其安全性。方法32例老年晚期胰腺癌患者随机分为吉西他滨加替吉奥(对照组),吉西他滨加替吉奥联合沙利度胺(联合组),2 w后评价治疗效果、安全性。结果对照组和联合组无进展生存时间(PFS)分别为2. 7个月(95%CI为2. 3～3. 1个月)和3. 0个月(95%CI为2. 5～3. 4个月),差异有统计学意义(P<0. 05);总生存时间(OS)分别为6. 0个月(95%CI为5. 2～5. 9个月)和6. 1个月(95%CI为5. 1～7. 3个月,P>0. 05)。对照组部分缓解(PR) 1例,疾病稳定(SD) 6例,疾病进展(PD) 9例;联合组PR 1例,SD7例,PD 8例;两组疾病有效率无统计学差异(P=0. 371)。两组毒副反应主要为Ⅱ～Ⅲ度腹泻。结论吉西他滨加替吉奥联合沙利度胺三联方案安全有效,副作用相对易耐受,可一定程度延长老年晚期胰腺癌患者的生存期。

Objective To investigate the clinical efficacy of gemcitabine gatifao combined with thalidomide in the treatment of advanced pancreatic cancer and observe the efficacy and safety of thalidomide combined with the regimen of tegiloga and gemcitabine in the treatment of advanced pancreatic cancer.Methods 32 patients with advanced pancreatic cancer were randomly divided into gemcitabine gatifao(control group),gemcitabine giantrepine and thalidomide(combined group)by random number method.The treatment effect and safety of the two groups of patients were evaluated after 2 cycles.Results Progression-free survival(PFS)was 2.7 months(95%CI 2.3~3.1 months)and 3.0 months(95%CI 2.5~3.4 months)in patients of control and combined groups,there were statistically significant differences(P<0.05).Total survival time(OS)was 6.0 months(95%CI 5.2~5.9)and 6.1 months(95%CI 5.1~7.3,P>0.05),respectively.In control group,there were 1 case of partial remission(PR),6 cases of stable disease(SD),and 9 cases of disease progression(PD).Among the 16 patients in combined group,PR was 1,SD7 and PD 8.The disease efficiency of patients in control and combined groups was not statistically significant(P=0.371).Two groups of patients with adverse reaction wasⅡ~Ⅲdegree of diarrhea.Conclusions The combination of gemcitabine gatifao and thalidomide is safe and effective and the side effects are relatively easy to tolerate,which can extend the survival period of patients with advanced pancreatic cancer to some extent.